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Resistance to anticancer drugs used in the clinic 
has led to the persistence of tumor growth and the 
failure of chemotherapeutic regimens. Methotrexate 
(MTX) has been used as a chemotherapeutic agent 
for the management of tumors of varied origins. The 
patients presenting with oral carcinoma at our institute 
are predominantly habitual chewers of pan, areca 
nut and tobacco [1, 2]. Characterization of this class 
of neoplasia with unique etiology showed that the ma-
jority of these neoplasia are squamous cell carcinoma 
(SCC) and they express certain tumor-specific mar-
kers such as the carcinoembryonic antigen [3]. For oral 
cancers patients (prevalently of T3/T4 stages), MTX 
is administered to reduce the tumor mass for further 
management with radiotherapy and/or surgery and 
as a palliative option. Earlier studies on administration 
of MTX as a single agent or in combination with other 
chemotherapeutic agents as well as other modalities 
of therapy such as radiation has shown varying de-
grees of success for head and neck cancers [4–6]. 
A number of factors are critical for a favorable 
clinical outcome of MTX therapy. These include ele-
vated levels of the target, dihydrofolate reductase 
(DHFR), diminished polyglutamation and transport 
of MTX as well as altered binding affinity of DHFR 
to MTX. Translational control of DHFR, including feed 
back mechanisms in DHFR biosynthesis could also 
contribute to MTX resistance [7, 8]. Multiple mecha-
nisms for MTX resistance in a clinical setting for head 
and neck carcinoma has been proposed [9], and the 
implications of the various pathways for clinical MTX 
resistance has also been reviewed [10]. 
The current study was undertaken to evaluate the 
sensitivity of oral cancer cells to MTX in vitro and its 
association with clinical response to MTX in oral cancer 
patients.
Patient selection and treatment. Patients were 
treated at the Dental Division of Kidwai Memorial Insti-
tute of Oncology, Bangalore, India and were randomly 
included in the study. Informed patient consents were 
obtained, and approved treatment protocols were admi-
nistered. In addition, patients who had advanced disease 
were put through a screening committee to start che-
motherapy for palliation. All the patients (35 to 65 years 
old) recruited in the study received chemotherapy with 
weekly MTX injections at the dose of 50 mg IM. A maxi-
mum of five injections were administered. During the 
treatment period, the patients were monitored for total 
WBC count, nausea, vomiting and mucositis. All clinical 
assessments of the response were made after the che-
motherapy phase to evaluate the correlation between the 
in vitro sensitivity to MTX and tumor response. Some pa-
tients subsequently received radiotherapy, two patients 
received radiotherapy prior to MTX therapy.
Criteria for clinical response. The following crite-
ria were used for the assessment of clinical response. 
Complete response: total disappearance of the clini-
cally viable lesion; partial response: > 50% reduction 
in tumor size; minimal response: < 50% reduction 
in tumor size; and no response: stable disease.
Chemicals used in the assay. Trypan blue, Col-
lagenase IV, Hanks Balanced Salt Solution (HBSS) 
were all obtained from Sigma Chemical Co (St. Louis, 
MO, USA). MTX was a kind gift from Dr. R.M. Lalitha. 
MTX dissolved in L-15 tissue culture media was used 
in the study. The L-15 tissue culture medium with 
composition identical to that of GIBCO BRL, USA was 
used. Final assay medium contained L-15 medium 
supplemented with 10% fetal bovine serum (FBS).
Preparation of cell suspensions from tumor 
tissue. Tumor biopsy samples prior to treatment were 
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placed in HBSS at 4 °C. To generate tumor cell suspen-
sions from the biopsies, the tissue was minced using 
scissors in a watch glass. The minced tissue was sus-
pended in 0.075% collagenase for 30 min at 37 °C to ob-
tain single cell suspensions for the assay. The larger 
clumps were discarded after the initial centrifugation 
(27 x g). The supernatants were further subjected 
to a centrifugation at 475 x g. An aliquot of the cell sus-
pension was mixed with equal volume of trypan blue 
solution, mixed gently and placed in a hemacytometer, 
and the number of viable cells in the suspension.
Drug sensitivity assay. Cultured oral cancer cells 
were maintained in L-15 media supplemented with 
10% FBS, and treated at three different concentrations 
of MTX (0.25 µM, 25 µM, and 75 µM) for 24 h at 37 °C. 
The highest concentration was selected based on the 
use of similar concentrations for MTX-resistant human 
cells in earlier studies [11].
Assessment of cell viability in vitro. After 
24 h of incubation with MTX, aliquots of cell samples 
were mixed gently with equal volume of trypan blue 
dye solution and immediately examined using light 
microscopy. Viable cells were counted in triplicates 
for each MTX concentration per sample. Results were 
presented as mean ± standard deviation.
Criteria for in vitro sensitivity. The cells were 
scored as sensitive, moderately sensitive, moder-
ately resistant and resistant, based on the LC50 values 
(LC50: lethal concentration inducing 50% of cell death). 
If the LC50 was achieved at the lowest concentration 
(0.25 µM), the tumor cell populations were considered 
as sensitive, whereas inability to attain LC50 even at the 
highest concentration used (75 µM) would render them 
to be classified as resistant. If LC50 was in the proximi-
ty of 25 µM MTX the tumor cells were designated 
as moderately sensitive.  Attaining LC50 at the highest 
concentration (75 µM) rendered them to be classified 
as moderately resistant. 
The study was performed on 10 oral tumors 
of T4 stage (50%), T3 stage (30%), or T2 stage (20%); 
staging from T2N0 to T4N3 (Table 1). Four patients 
presented with carcinomas of the buccal mucosa and 
four with carcinoma of the alveolus. There was one 
presentation with carcinoma of the floor of the mouth, 
and one locoregional extension of the carcinoma of the 
buccal mucosa to tongue. 
Table 1. Clinical characteristics of patient samples used in the study
Patient 
No. Age Sex Site of Lesion
# Stage 
of Tumor Histological type, grade
1 45 F Ca BM T4N3 Squamous carcinoma
2 52 M Ca tongue (L) T2N0 Verrucous
3 42 F Ca BM (R) T3N1 Squamous carcinoma, Gr II
4 35 F Ca alveolus(L) T4N1 Squamous carcinoma, Gr II
5 45 F Ca alveolus(L) T4N1 Squamous carcinoma, Gr III
6 55 F Ca alveolus(L) T3N1 Squamous carcinoma, Gr III/IV
7 58 F Ca alveolus(L) T4N0 Squamous carcinoma, Gr II
8 65 F Ca BM (R) T3N1 Verrucous
9 60 M Ca floor of mouth T4N1 Squamous carcinoma, Gr III
10 35 F Ca BM (R) T2N1 Squamous carcinoma, Gr II
Notes: #BM — buccal mucosa; R — right; L — left.
Differential sensitivity to MTX was observed among 
the various tumor cells in the in vitro assay, and these 
data were compared to the clinical outcome (Figure 
and Table 2). In case 1, tumors cells were found 
to be sensitive to MTX, and the laboratory data from 
patient 1 corresponded to a good clinical response. 
In case 2, in vitro response of tumor cells was modera-
tely sensitive, but clinical response in that patient was 
good. In cases 3 and 7, moderate resistance of tumor 
cells in vitro and moderate response or good response 
in clinical conditions were registered, respectively. Tu-
mor cells from cases 5, 6, 8–10 were resistant to MTX 
in vitro, and in all these cases clinical response on MTX 
therapy was moderate or absent. 
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Figure. The cell viability was assessed by using trypan blue 
dye exclusion assay. Mean of triplicate treatments ± standard 
deviation is represented. Assays using tumor cells without inclu-
sion of MTX served as controls. Viable cells from controls were 
considered as 100% to determine the effect of MTX
Table 2. Correlation between in vitro sensitivity and clinical response 
to methotrexate
Patient 
No. Treatment
Clinical response 
to Methotrexate treatment Laboratory analysis (LC50, µM)
1 CT Good response Sensitive (< 0.25)
2 CT Good response Moderate Sensitive ( ~25 )
3 CT Moderate response Moderate resistance ( ~75 )
4 CT 50% response Variable (NE)
5 CT Moderate response Resistant (> 75 )
6 CT Resistant Resistant (> 75 )
7 CT Good response Moderate resistance (< 75 )
8 CT Resistant Resistant (> 75 )
9 RT + CT Resistant Resistant (> 75 )
10 RT + CT Resistant Resistant (> 75 )
Note. NE — not estimated.
Failure of anticancer chemotherapy is largely 
attribu ted to intrinsic or acquired resistance to anti-
cancer drugs. Our studies using cells from biopsies 
of oral tumors from patients prior to initiation of MTX 
treatment depict existence of intrinsic resistance to the 
drug in a number of cases. 
Our observations with oral carcinoma cells suggest, 
for the first time, that the intrinsic resistance to MTX could 
be a contributing factor in the lack of response of oral 
carcinoma to MTX in the clinic. The implications of various 
chemosensitivity assays and their extrapolation to in vivo 
scenario have been discussed in detail elsewhere [12, 13]. 
Studies on drug sensitivity of advanced cancers of gingi-
vo-buccal, tongue and floor of the mouth to va rious drugs 
showed that 52% of the tumors tested showed sensitivity 
to MTX with a good clinical correlation [14].
Future studies on a larger patient population could 
provide valuable information with respect to the genera-
lity of intrinsic MTX resistance in oral cancers in South In-
dia. Further, in vitro–in vivo correlation from such a study 
could provide directions for designing individuali zed 
therapies for this unique class of neoplasia.
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